Literature DB >> 7926494

Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group.

B Hallerbäck1, P Unge, L Carling, B Edwin, H Glise, N Havu, E Lyrenäs, K Lundberg.   

Abstract

BACKGROUND/AIMS: Patients with reflux esophagitis have rapid relapses after treatment withdrawal. This study was designed to investigate the relapse rate of symptomatic esophagitis during maintenance treatment with omeprazole or ranitidine.
METHODS: Patients with endoscopically verified acute erosive or ulcerative esophagitis were initially treated with 20-40 mg omeprazole daily for 8-12 weeks. After healing, the patients were randomized to maintenance treatment with omeprazole (20 or 10 mg each morning) or ranitidine (150 mg twice daily). Control endoscopy was performed at the end of the healing phase and after 12 months of maintenance treatment or symptomatic relapse.
RESULTS: Of 426 initially treated patients, 392 were healed and entered the maintenance study. The months of maintenance treatment with 20 mg omeprazole once daily (n = 131), 10 mg omeprazole once daily (n = 133), and 150 mg ranitidine twice daily (n = 128) were 72%, 62%, and 45%, respectively. Both the 10- and 20-mg doses of omeprazole were significantly better than the dose of ranitidine (P < 0.001 and P < 0.005, respectively). There was no significant difference between the 10- and 20-mg doses of omeprazole (P = 0.06).
CONCLUSIONS: Maintenance treatment with omeprazole (20 or 10 mg once daily) is superior to ranitidine (150 mg twice daily) in keeping patients with erosive reflux esophagitis in remission over a 12-month period.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7926494     DOI: 10.1016/0016-5085(94)90531-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  36 in total

Review 1.  Advances in minimally invasive esophageal surgery.

Authors:  T R Eubanks; C A Pellegrini
Journal:  Curr Gastroenterol Rep       Date:  1999-06

2.  Early and late results of the acid suppression and duodenal diversion operation in patients with barrett's esophagus: analysis of 210 cases.

Authors:  Attila Csendes; Patricio Burdiles; Italo Braghetto; Owen Korn; Juan Carlos Díaz; Jorge Rojas
Journal:  World J Surg       Date:  2002-03-01       Impact factor: 3.352

3.  Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Kazuro Ikawa; Norifumi Morikawa; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

4.  Reappraisal of bicarbonate secretion by the human oesophagus.

Authors:  A Mertz-Nielsen; J Hillingsø; K Bukhave; J Rask-Madsen
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

5.  Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?

Authors:  Tomohiko Shimatani; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Susumu Tazuma; Masaki Inoue
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

Review 6.  Medical management of gastro-oesophageal reflux disease.

Authors:  J S Collins
Journal:  Ir J Med Sci       Date:  1996 Jul-Sep       Impact factor: 1.568

7.  Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer.

Authors:  R J Brummer; R W Stockbrügger
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

Review 8.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model.

Authors:  Joseph Romagnuolo; Michael A Meier; Daniel C Sadowski
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

10.  Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo.

Authors:  K D Bardhan; P Cherian; A Vaishnavi; R B Jones; M Thompson; P Morris; A Brooks; J D'Silva; K R Gillon; C Wason; J Patterson; J Polak; A Bishop
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.